206 related articles for article (PubMed ID: 34410012)
21. Xenobiotic Nuclear Receptor Signaling Determines Molecular Pathogenesis of Progressive Familial Intrahepatic Cholestasis.
Kim KH; Choi JM; Li F; Arizpe A; Wooton-Kee CR; Anakk S; Jung SY; Finegold MJ; Moore DD
Endocrinology; 2018 Jun; 159(6):2435-2446. PubMed ID: 29718219
[TBL] [Abstract][Full Text] [Related]
22. Dehydrodiconiferyl alcohol, a lignan from Herpetospermum pedunculosum, alleviates cholestasis by activating pathways associated with the farnesoid X receptor.
Wei X; Ma Y; Dong Z; Wang G; Lan X; Liao Z; Chen M
Phytomedicine; 2021 Jan; 80():153378. PubMed ID: 33113499
[TBL] [Abstract][Full Text] [Related]
23. miR-199a-5p inhibits the expression of ABCB11 in obstructive cholestasis.
Balasubramaniyan N; Devereaux MW; Orlicky DJ; Sokol RJ; Suchy FJ
J Biol Chem; 2021 Dec; 297(6):101400. PubMed ID: 34774795
[TBL] [Abstract][Full Text] [Related]
24. Hepatic overexpression of murine Abcb11 increases hepatobiliary lipid secretion and reduces hepatic steatosis.
Figge A; Lammert F; Paigen B; Henkel A; Matern S; Korstanje R; Shneider BL; Chen F; Stoltenberg E; Spatz K; Hoda F; Cohen DE; Green RM
J Biol Chem; 2004 Jan; 279(4):2790-9. PubMed ID: 14570929
[TBL] [Abstract][Full Text] [Related]
25. Hesperidin alleviates cholestasis via activation of the farnesoid X receptor in vitro and in vivo.
Zhang G; Sun X; Wen Y; Shi A; Zhang J; Wei Y; Wu X
Eur J Pharmacol; 2020 Oct; 885():173498. PubMed ID: 32841642
[TBL] [Abstract][Full Text] [Related]
26. Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation.
Sheng L; Jena PK; Hu Y; Liu HX; Nagar N; Kalanetra KM; French SW; French SW; Mills DA; Wan YY
J Pathol; 2017 Dec; 243(4):431-441. PubMed ID: 28892150
[TBL] [Abstract][Full Text] [Related]
27. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation.
Degirolamo C; Modica S; Vacca M; Di Tullio G; Morgano A; D'Orazio A; Kannisto K; Parini P; Moschetta A
Hepatology; 2015 Jan; 61(1):161-70. PubMed ID: 24954587
[TBL] [Abstract][Full Text] [Related]
28. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice.
Wagner M; Fickert P; Zollner G; Fuchsbichler A; Silbert D; Tsybrovskyy O; Zatloukal K; Guo GL; Schuetz JD; Gonzalez FJ; Marschall HU; Denk H; Trauner M
Gastroenterology; 2003 Sep; 125(3):825-38. PubMed ID: 12949728
[TBL] [Abstract][Full Text] [Related]
29. Paradoxical Effects of Emodin on ANIT-Induced Intrahepatic Cholestasis and Herb-Induced Hepatotoxicity in Mice.
Wang X; Han L; Bi Y; Li C; Gao X; Fan G; Zhang Y
Toxicol Sci; 2019 Mar; 168(1):264-278. PubMed ID: 30517764
[TBL] [Abstract][Full Text] [Related]
30. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
[TBL] [Abstract][Full Text] [Related]
31. Farnesoid X Receptor Activation Promotes Hepatic Amino Acid Catabolism and Ammonium Clearance in Mice.
Massafra V; Milona A; Vos HR; Ramos RJJ; Gerrits J; Willemsen ECL; Ramos Pittol JM; Ijssennagger N; Houweling M; Prinsen HCMT; Verhoeven-Duif NM; Burgering BMT; van Mil SWC
Gastroenterology; 2017 May; 152(6):1462-1476.e10. PubMed ID: 28130067
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer.
Liu T; Yang H; Fan W; Tu J; Li TWH; Wang J; Shen H; Yang J; Xiong T; Steggerda J; Liu Z; Noureddin M; Maldonado SS; Annamalai A; Seki E; Mato JM; Lu SC
Gastroenterology; 2018 Aug; 155(2):557-571.e14. PubMed ID: 29733835
[TBL] [Abstract][Full Text] [Related]
33. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
[TBL] [Abstract][Full Text] [Related]
34. Histone H3K4 trimethylation by MLL3 as part of ASCOM complex is critical for NR activation of bile acid transporter genes and is downregulated in cholestasis.
Ananthanarayanan M; Li Y; Surapureddi S; Balasubramaniyan N; Ahn J; Goldstein JA; Suchy FJ
Am J Physiol Gastrointest Liver Physiol; 2011 May; 300(5):G771-81. PubMed ID: 21330447
[TBL] [Abstract][Full Text] [Related]
35. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
36. Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis.
Byun S; Jung H; Chen J; Kim YC; Kim DH; Kong B; Guo G; Kemper B; Kemper JK
J Biol Chem; 2019 May; 294(22):8732-8744. PubMed ID: 30996006
[TBL] [Abstract][Full Text] [Related]
37. SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling.
García-Rodríguez JL; Barbier-Torres L; Fernández-Álvarez S; Gutiérrez-de Juan V; Monte MJ; Halilbasic E; Herranz D; Álvarez L; Aspichueta P; Marín JJ; Trauner M; Mato JM; Serrano M; Beraza N; Martínez-Chantar ML
Hepatology; 2014 May; 59(5):1972-83. PubMed ID: 24338587
[TBL] [Abstract][Full Text] [Related]
38. Editor's Highlight: Clofibrate Decreases Bile Acids in Livers of Male Mice by Increasing Biliary Bile Acid Excretion in a PPARα-Dependent Manner.
Zhang Y; Lickteig AJ; Csanaky IL; Klaassen CD
Toxicol Sci; 2017 Dec; 160(2):351-360. PubMed ID: 28973556
[TBL] [Abstract][Full Text] [Related]
39. β-Catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis.
Thompson MD; Moghe A; Cornuet P; Marino R; Tian J; Wang P; Ma X; Abrams M; Locker J; Monga SP; Nejak-Bowen K
Hepatology; 2018 Mar; 67(3):955-971. PubMed ID: 28714273
[TBL] [Abstract][Full Text] [Related]
40. Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity.
Chen F; Ananthanarayanan M; Emre S; Neimark E; Bull LN; Knisely AS; Strautnieks SS; Thompson RJ; Magid MS; Gordon R; Balasubramanian N; Suchy FJ; Shneider BL
Gastroenterology; 2004 Mar; 126(3):756-64. PubMed ID: 14988830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
